HK StockDetailed Quotes

Provided by Tiger Trade Technology Pte. Ltd.

Sub-New Stocks

317.720

-3.774-1.17%

Number of Gainers:18

Number of Losers:29

Number of Flat:12

PE:- -

High:321.632

Open:321.494

Low:317.323

Close:321.494

Volume:95.12M

Turnover:2.82B

Market Cap:751.52B

Float Cap:670.67B

Loading ...

Hutchmed China Ltd - Hutchmed Licenses Kras-Egfr-Antibody to GSK

THOMSON REUTERS

港股动态：携程股价重挫逾4%，增长减速预期与多重宏观压力引发市场忧虑

Keymed Biosciences Climbs on Licensing Deal with Aeira Pte

Hutchmed (China) Signs Exclusive Licensing Deal with GSK for Investigational Cancer Drug

Hutchmed (China) - to Start Global Phase 1 Development Program in H2 2026

THOMSON REUTERS

Hutchmed Licenses KRAS-EGFR Antibody Conjugate HMPL-A830 to GSK for USD 110 Million Upfront

Hutchmed (China) - Agreement Includes $110 Mln Upfront, up to $1.30 Bln in Milestones, Plus Royalties

THOMSON REUTERS

Hutchmed Announces Licensing Agreement with GSK for Kras-Egfr-Antibody Conjugate Cancer Therapy

THOMSON REUTERS

Keymed Biosciences Signs Licensing Deal for Kangyueda in 18 Markets

Sanxun Holdings Group Announces Winding up Petition

Keymed Biosciences Licenses Stapokibart Marketing, Sales Rights in 18 Southeast and Central Asia Markets to Aeira

KeyMed Biosciences - Aeira Responsible for Registration and Commercialization of Stapokibart Injection in 18 Countries and Regions

THOMSON REUTERS

KeyMed Biosciences - Enters Exclusive Licensing Agreement with Aeira Pte for Stapokibart Injection

THOMSON REUTERS

Yuexiu Services Files Board, Board Committee Member List with Disclosure Duties

Yuexiu Services Appoints Chen Yujun as Non-Executive Director

Kindstar Globalgene Files HKEX Next-Day Disclosure Return on Share Buyback Cancellation

NAYUKI Spends HK$1.64 Million to Buy Back 2.35 Million Shares on September 2

Nayuki Files HKEX Next-Day Disclosure Return Reporting Share Buyback at HKD 0.7 Per Share

Zhang Guangdi Raises Stake in Chaoju Eye Care with Share Acquisition

Bairong Files HKEX Next-Day Disclosure Return Reporting Share Repurchase at HKD 5.39 Each

{"basename":"","ssrTDKData":{"titleTemplate":"%s - Tiger Brokers","title":"Tiger Brokers HK | Online Trading in stocks, bonds & ETFS","description":"Discover Tiger Brokers HK, an online trading platform for stocks&ETFs, options&futures, bonds and crypto. Open an account to enjoy low commission trading today!","keywords":"tiger trading,tiger security,tiger broker hk,tigers co ltd,tiger trade hk,tiger brokers hk,stock broker,securities broker,online brokerage,hong kong broker,hk broker,online stock trading,online trading platform,stock trading platforms,trading application,stock trading,stock trading hong kong,buying stocks in hong kong,tiger brokers","social":{"ogDescription":"Discover Tiger Brokers HK, an online trading platform for stocks&ETFs, options&futures, bonds and crypto. Open an account to enjoy low commission trading today!","ogImage":"https://c1.itigergrowtha.com/portal5/static/media/og-logo.0a0bd8dc.png","ogUrl":"https://www.imtigers.com/stock/BK1587/news?page=8"},"companyName":"Tiger Brokers"},"pageData":{"isMobile":false,"isTiger":false,"isTTM":true,"region":"HKG","license":"TBHK","edition":"fundamental","symbol":"BK1587","isAnalysisPage":false},"__swrFallback__":{"@#url:\"https://hq.skytigris.cn/stock_info/detail/global\",params:#delay:false,,method:\"POST\",data:#items:@#symbol:\"BK1587\",,,,,undefined,":{"symbol":"BK1587","market":"HK","secType":"PLATE","nameCN":"Sub-New Stocks","latestPrice":317.7199,"timestamp":1789458380878,"preClose":321.4935,"halted":0,"volume":95120546,"delay":0,"changeRate":-0.011738,"floatShares":0,"shares":0,"eps":0,"marketStatus":"Trading","change":-3.77359,"latestTime":"09-15 15:46:21","open":321.4935,"high":321.6318,"low":317.323,"amount":2815086708,"amplitude":0.013402,"askPrice":0,"askSize":0,"bidPrice":0,"bidSize":0,"shortable":3,"etf":0,"tradingStatus":0,"nextMarketStatus":{"tag":"Closed","tradingStatus":0,"beginTime":1789459800000},"marketStatusCode":0,"adr":0,"adjPreClose":0,"openAndCloseTimeList":[[1789435800000,1789444800000],[1789448400000,1789459200000]],"pbRate":1.333505,"peRate":15.193809,"turnoverRate":0.00199,"increases":18,"decrements":29,"flats":11,"marketCap":751517628056,"floatMarketCap":670673467968},"@#url:\"https://hq.skytigris.cn/stock_info/fundamental/all\",params:#delay:false,,method:\"POST\",data:#items:@#symbol:\"BK1587\",,,,,undefined,":{"symbol":"BK1587","high":321.6318,"amplitude":0.013402,"preClose":321.4935,"low":317.323,"pbRate":"1.333505","latestPrice":317.7199,"volume":95120546,"delay":0,"open":321.4935,"prevYearClose":478.5753,"prevWeekClose":317.484,"prevMonthClose":342.657,"prevQuarterClose":326.657,"fiveDayClose":331.343,"twentyDayClose":346.944,"sixtyDayClose":348.36,"secType":"PLATE","market":"HK","turnoverRate":0.00199,"peRate":15.193809,"marketCap":751517628056,"floatMarketCap":670673467968,"timestamp":1789458380878,"nameCN":"Sub-New Stocks"},"@#url:\"https://hq.skytigris.cn/api/global/plate/up_down\",method:\"POST\",data:#delay:false,bkCodes:@\"BK1587\",,,,undefined,":{"bkCode":"BK1587","up":18,"down":29,"flat":12},"$inf$@#url:\"https://stock-news.skytigris.cn/v2/news/list\",params:#symbols:\"BK1587\",pageSize:20,pageCount:8,lang_content:\"en\",edition:\"fundamental\",,,undefined,":[{"items":[{"id":"2664829237","title":"Hutchmed China Ltd - Hutchmed Licenses Kras-Egfr-Antibody to GSK","url":"https://stock-news.laohu8.com/highlight/detail?id=2664829237","media":"THOMSON REUTERS","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2664829237?lang=en_us&edition=fundamental","pubTime":"2026-09-03 14:00","pubTimestamp":1788415206,"startTime":"0","endTime":"0","summary":null,"market":"nz","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://api.refinitiv.com/data/news/v1/stories/urn:newsml:reuters.com:20260903:nTUCB6PVNL:1","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"reuters_en_live","symbols":["LU0971552673.USD","LU2646069778.SGD","LU1400636491.USD","LU2468319806.SGD","BK5011","LU1309081286.SGD","LU0225771236.USD","LU0225284248.USD","LU0987226296.USD","LU1400636574.HKD","LU1487256676.USD","IE00BWDBJ516.SGD","LU0971552830.HKD","LU0545562505.USD","LU1035777561.USD","SG9999001176.SGD","LU1064927863.SGD","LU0575583348.USD","BK1191","IE0034235071.USD","LU0058720904.USD","LU0161305163.EUR","LU1481600234.SGD","LU1645745479.HKD","BK1587","LU0306806265.USD","LU0306807586.USD","LU2089984988.USD","SG9999001176.USD","LU0289739699.SGD","LU0557290698.USD","IE00BQJZX424.USD","SGXZ57979304.SGD","LU1983299246.USD","GSK.UK","00013","LU0321505868.SGD","SG9999013999.USD","LU0225283273.USD","LU1302929846.USD","LU1015430645.USD","LU0203345920.USD","BK1588","LU1046248800.SGD","IE00B3T34201.USD","LU0211331839.USD","LU0985481810.HKD","LU1228905540.USD","LU1098665638.USD","LU1400636657.SGD"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"1185045258","title":"港股动态：携程股价重挫逾4%，增长减速预期与多重宏观压力引发市场忧虑","url":"https://stock-news.laohu8.com/highlight/detail?id=1185045258","media":"Stock News","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/1185045258?lang=en_us&edition=fundamental","pubTime":"2026-09-03 13:50","pubTimestamp":1788414618,"startTime":"0","endTime":"0","summary":"携程集团-S(09961)今日股价表现疲软，盘中跌幅超过4%，暂时领跌蓝筹股板块。截至发稿时，该股下跌4.6%，报328港元，成交额达到6.73亿港元。消息面上，携程集团于昨晚宣布，计划在9月14日召开董事会会议，旨在审议并批准截至2026年6月30日止三个月及六个月的财务业绩及相关公告。此前，公司已发出业绩预警，预计第二季度净营业收入同比增幅将收窄至3%至8%区间。这一预期增速较第一季度出现显著...","market":"sg","thumbnail":"","type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"-1","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["LU0054237671.USD","IE00BPRC5H50.USD","HK0000306701.USD","LU0348735423.USD","LU0828238088.HKD","LU0463099449.HKD","LU0868486357.SGD","LU0823426480.USD","LU1868838027.USD","LU0107464264.USD","LU0181495838.USD","LU0708995583.HKD","LU2023250504.SGD","VXUS","IE0003851619.USD","LU0143863198.USD","LU0516422952.EUR","LU1720050803.USD","LU0307460666.USD","LU0572944931.SGD","LU0228659784.USD","LU0210526637.USD","LU0871576103.HKD","LU2152927971.USD","LU1868837722.USD","LU2449936058.SGD","LU0823426308.USD","LU0605514214.HKD","LU1813983027.USD","LU0594300419.USD","LU0164865239.USD","IE00B0JY6N72.USD","BEDZ","LU1880383440.USD","LU2424517915.HKD","LU1974910355.USD","LU1242518931.SGD","LU0048575426.USD","LU2039709279.SGD","LU2153591404.USD","LU1102505929.USD","SG9999002562.SGD","LU0143863784.USD","LU0106252389.USD","SG9999001093.SGD","LU0348825331.USD","IE0008368742.USD","LU0561508036.HKD","IE00B8L5B284.USD","SG9999011746.SGD","HK0000320223.HKD","LU0979878070.USD","09961","LU0384037296.USD","LU1224709979.USD","LU0244354667.USD","BK4142","LU0593848301.USD","LU0287142896.SGD","LU2399975544.HKD","LU0359202008.SGD","LU0164880469.USD","LU1868837565.USD","BK4526","LU0516423174.USD","LU1328277881.USD","LU0431992006.USD","LU0594300179.USD","BK1588","LU0011963245.USD","LU0231483743.USD","LU0211977185.USD","IE0003795394.USD","LU0737861772.HKD","LU1102505762.USD","KCAI","HK0000320264.USD","SG9999000459.SGD","LU0516422440.USD","LU0327786744.USD","LU0828237510.HKD","LU0509642566.USD","LU0049853897.USD","LU0269904917.USD","LU1808992512.USD","LU0039217434.USD","LU1023057109.AUD","LU0251143458.SGD","LU0320764599.SGD","BK4588","IE0008369823.USD","LU0173614495.USD","LU0329678337.USD","LU1303224171.USD","LU1719994722.HKD","IE00B031HY20.USD","LU0455707207.USD","LU0737861699.HKD","LU0315179316.USD","LU2778985437.USD","SG9999002463.SGD","IE0034224299.USD","LU0456827905.SGD","LU0516422366.SGD","LU1917777945.USD","LU2348773727.SGD","LU0488056044.USD","BK4531","LU2106854487.HKD","BK1164","BK1587","LU0348827113.USD","LU0329678170.USD","LU1794554557.SGD","LU0650527681.SGD","IE00B543WZ88.USD","SG9999001903.USD","LU0370786039.SGD","BK1604","LU0149721374.USD","LU0531971595.HKD","LU0261950983.USD","LU1328615791.USD","LU0588546209.SGD","LU2242644610.SGD","TCOM","LU1188198961.HKD","LU0502904849.HKD","LU1770034418.SGD","LU0516423091.SGD","LU2476274720.SGD","LU1481107354.HKD","IE00B3M56506.USD","LU0359201612.USD","LU0052750758.USD","LU1956131251.USD","SG9999000418.SGD","LU0261950470.USD","LU0051755006.USD","SG9999000475.SGD","LU1282649067.USD","LU0823397103.USD","LU0823397285.USD","LU0314109678.HKD","HK0000306685.HKD","IE00B8HQ1Z84.USD","LU1242518857.USD","LU1880383366.USD","LU1282649810.SGD","LU0417516902.SGD","LU1961090484.USD","BK4585","LU0048580855.USD","LU0359201885.HKD","LU0540923850.HKD","LU0417516738.SGD","LU3063872942.SGD","LU0828237940.HKD","LU1251922891.USD","BK1615","LU0456846285.SGD","LU2476274308.USD","LU0634319403.HKD","LU0326950275.SGD","BK4534","IE00B5MMRT66.SGD"],"isVideo":false,"video":null,"gpt_icon":1},{"id":"2664826668","title":"Keymed Biosciences Climbs on Licensing Deal with Aeira Pte","url":"https://stock-news.laohu8.com/highlight/detail?id=2664826668","media":"Reuters","labels":["corporation"],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2664826668?lang=en_us&edition=fundamental","pubTime":"2026-09-03 12:31","pubTimestamp":1788409914,"startTime":"0","endTime":"0","summary":"BUZZ-Keymed Biosciences climbs on licensing deal with Aeira Pte** Shares of Keymed Biosciences Inc2162.HKclimb 2.9% in the third straight rising session to HK$80, their highest level since August 27** Keymed says it entered into an exclusive licensing agreement with pharmaceutical firm Aeira Pte, on marketing registration and commercialization of Stapokibart injection - an antibody drug for treatment of topic dermatitis, in 18 countries and regions including Southeast and Central Asia** Keymed says it will receive an upfront payment, milestone payments and commercialization milestone payments and it is entitled to receive royalties of up to a high double-digit percentage based on product net sales in the licensed territory** YTD, stock up 46.7%, Hang Seng Biotech Index.HSBIOup 10.6%","market":"us","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://api.refinitiv.com/data/news/v1/stories/urn:newsml:reuters.com:20260903:nL1N44V04C:1","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"corporation","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["02162","BK1583","BK1161","BK1587","BK1574"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2664826376","title":"Hutchmed (China) Signs Exclusive Licensing Deal with GSK for Investigational Cancer Drug","url":"https://stock-news.laohu8.com/highlight/detail?id=2664826376","media":"Reuters","labels":["corporation"],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2664826376?lang=en_us&edition=fundamental","pubTime":"2026-09-03 12:22","pubTimestamp":1788409371,"startTime":"0","endTime":"0","summary":"HUTCHMED  signs exclusive licensing deal with GSK for investigational cancer drugSept 3 -HUTCHMED 0013.HKsaid on Thursday its unit had signed an exclusive development and licensing agreement with a subsidiary of GSKGSK.Lto develop and commercialise its investigational cancer drug, HMPL-A830.The agreement grants the British drug maker's unit worldwide rights to develop and commercialise the drug outside Mainland China, Hong Kong, Macau and Taiwan.","market":"nz","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://api.refinitiv.com/data/news/v1/stories/urn:newsml:reuters.com:20260903:nL4N44V0AL:1","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"corporation","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["LU0203347892.USD","LU0321505868.SGD","00013","BK5011","BK1191","IE00BQJZX424.USD","LU1098665638.USD","SG9999001176.USD","LU0058720904.USD","LU0985481810.HKD","LU0575583348.USD","LU1309081286.SGD","LU1645745479.HKD","IE00B3T34201.USD","LU1228905540.USD","LU0161305163.EUR","LU1487256676.USD","LU1046248800.SGD","LU2089984988.USD","LU0211331839.USD","LU2646069778.SGD","LU1670756490.USD","LU0225283273.USD","LU0545562505.USD","LU1035777561.USD","LU1481600234.SGD","LU0289739699.SGD","LU1228905037.USD","BK1588","LU0971552673.USD","IE00BWDBJ516.SGD","LU0971552830.HKD","LU0987226296.USD","IE0034235071.USD","BK1587","GSK.UK","LU0557290698.USD","LU0306807586.USD","SG9999013999.USD","LU1400636574.HKD","LU1202635105.USD","LU1400636491.USD","LU1015430645.USD","LU0109981661.USD","LU0321505439.SGD","LU1481599808.USD","LU1983299246.USD","LU1302929846.USD","SG9999001176.SGD","LU0225771236.USD"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2664257978","title":"Hutchmed (China) - to Start Global Phase 1 Development Program in H2 2026","url":"https://stock-news.laohu8.com/highlight/detail?id=2664257978","media":"THOMSON REUTERS","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2664257978?lang=en_us&edition=fundamental","pubTime":"2026-09-03 12:01","pubTimestamp":1788408108,"startTime":"0","endTime":"0","summary":null,"market":"nz","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://api.refinitiv.com/data/news/v1/stories/urn:newsml:reuters.com:20260903:nFWN44U14F:3","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"reuters_en_live","symbols":["00013","BK1588","BK1191","BK1587"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2664825782","title":"Hutchmed Licenses KRAS-EGFR Antibody Conjugate HMPL-A830 to GSK for USD 110 Million Upfront","url":"https://stock-news.laohu8.com/highlight/detail?id=2664825782","media":"Reuters","labels":["corporation"],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2664825782?lang=en_us&edition=fundamental","pubTime":"2026-09-03 12:00","pubTimestamp":1788408027,"startTime":"0","endTime":"0","summary":"HUTCHMED licenses KRAS-EGFR antibody conjugate HMPL-A830 to GSK for USD 110 million upfrontHUTCHMED entered an exclusive licensing deal with GSK for HMPL-A830, a KRAS-EGFR antibody-drug conjugate canc","market":"us","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://api.refinitiv.com/data/news/v1/stories/urn:newsml:reuters.com:20260903:nNDL3PRfLc:1","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"corporation","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["IE00BGHQF748.EUR","BK4112","IE00BKPKM429.USD","LU2095319765.USD","LU0314104364.USD","LU2210149790.SGD","BK4588","BK1587","BK1588","NDAQ","SG9999014039.USD","IE00BN0W2T93.GBP","BK4585","IE00BN0W2W23.USD","SG9999014021.USD","SG9999014013.SGD","IE00BQXX3C00.GBP","BK1191","BCDF","IE00BQXX3D17.EUR","IE00B64PRP62.GBP","SG9999014005.SGD","IE00BQXX3F31.USD","IE00B3QW5Z07.USD","LU2210150020.SGD","00013","IE00BN0W2V16.EUR"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2664282520","title":"Hutchmed (China) - Agreement Includes $110 Mln Upfront, up to $1.30 Bln in Milestones, Plus Royalties","url":"https://stock-news.laohu8.com/highlight/detail?id=2664282520","media":"THOMSON REUTERS","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2664282520?lang=en_us&edition=fundamental","pubTime":"2026-09-03 12:00","pubTimestamp":1788408000,"startTime":"0","endTime":"0","summary":null,"market":"nz","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://api.refinitiv.com/data/news/v1/stories/urn:newsml:reuters.com:20260903:nTUA3XNFM8:2","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"reuters_en_live","symbols":["BK1587","BK1191","00013","BK1588"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2664204825","title":"Hutchmed Announces Licensing Agreement with GSK for Kras-Egfr-Antibody Conjugate Cancer Therapy","url":"https://stock-news.laohu8.com/highlight/detail?id=2664204825","media":"THOMSON REUTERS","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2664204825?lang=en_us&edition=fundamental","pubTime":"2026-09-03 12:00","pubTimestamp":1788408000,"startTime":"0","endTime":"0","summary":null,"market":"us","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://api.refinitiv.com/data/news/v1/stories/urn:newsml:reuters.com:20260903:nTUA3XNFM8:1","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"reuters_en_live","symbols":["00013","BK1191","BK1587","BK1588"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2664582856","title":"Keymed Biosciences Signs Licensing Deal for Kangyueda in 18 Markets","url":"https://stock-news.laohu8.com/highlight/detail?id=2664582856","media":"MT Newswires","labels":["corporation"],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2664582856?lang=en_us&edition=fundamental","pubTime":"2026-09-03 09:42","pubTimestamp":1788399758,"startTime":"0","endTime":"0","summary":"Keymed Biosciences  has signed a licensing agreement with Singapore-based Aeira to market and sell Kangyueda in 18 markets across Central and Southeast Asia, according to a Wednesday bourse filing.Kangyueda is approved to treat moderate-to-severe atopic dermatitis in adults, chronic rhinosinusitis with nasal polyposis and seasonal allergic rhinitis, the filing said.Under the deal, Keymed will receive an upfront payment, milestone payments upon hitting certain targets and royalties in the high-double-digit percentage range based on regional sales.Aeira will be responsible for regulatory filings and the commercialization of Kangyueda in markets including Singapore, Malaysia, the Philippines, Thailand, Kazakhstan and Uzbekistan, as well as Hong Kong and Macau.Keymed will oversee the production and timely supply of Kangyueda to Aeira.","market":"hk","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":"b010cf239ffd4765bcd3edd8f767f746","theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://www.mtnewswires.com/","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":"Keymed Biosciences Signs Licensing Deal for Kangyueda in 18 Markets","news_tag":"corporation","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["BK1574","BK1583","BK1587","BK1161","02162"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2664485688","title":"Sanxun Holdings Group Announces Winding up Petition","url":"https://stock-news.laohu8.com/highlight/detail?id=2664485688","media":"Reuters","labels":["event"],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2664485688?lang=en_us&edition=fundamental","pubTime":"2026-09-02 23:32","pubTimestamp":1788363153,"startTime":"0","endTime":"0","summary":"BRIEF-Sanxun Holdings Group Announces Winding Up PetitionSept 2 -Sanxun Holdings Group Ltd6611.HK:WINDING UP PETITIONHEARING FOR WINDING-UP PETITION SCHEDULED FOR NOVEMBER 5, 2026GENNEX FINANCIAL MEDIA IS PETITIONER FOR WINDING-UP PETITIONWINDING-UP PETITION FILED AGAINST CO ON AUGUST 25, 2026NO WINDING-UP ORDER GRANTED BY HIGH COURT AS OF ANNOUNCEMENT DATEWINDING-UP PETITION HAS NO MATERIAL IMPACT ON BUSINESS OPERATIONS OR FINANCIAL POSITIONIN COURSE OF SEEKING LEGAL ADVICE FOR DETERMINING POSSIBLE ACTIONS IN RESPECT OF PETITIONFurther company coverage:6611.HK","market":"nz","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://api.refinitiv.com/data/news/v1/stories/urn:newsml:reuters.com:20260902:nFWN44T17P:1","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"-1","news_top_title":null,"news_tag":"event","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["BK1587","06611","BK1240"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2664478814","title":"Keymed Biosciences Licenses Stapokibart Marketing, Sales Rights in 18 Southeast and Central Asia Markets to Aeira","url":"https://stock-news.laohu8.com/highlight/detail?id=2664478814","media":"Reuters","labels":["corporation","express"],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2664478814?lang=en_us&edition=fundamental","pubTime":"2026-09-02 21:04","pubTimestamp":1788354268,"startTime":"0","endTime":"0","summary":"Keymed Biosciences licenses Stapokibart marketing, sales rights in 18 Southeast and Central Asia markets to AeiraKeymed entered an exclusive licensing deal with Aeira to register and commercialize Sta","market":"nz","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://api.refinitiv.com/data/news/v1/stories/urn:newsml:reuters.com:20260902:nNDL7LCJLF:1","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"corporation,express","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["BK1161","BK1583","BK1574","BK1587","02162"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2664814417","title":"KeyMed Biosciences - Aeira Responsible for Registration and Commercialization of Stapokibart Injection in 18 Countries and Regions","url":"https://stock-news.laohu8.com/highlight/detail?id=2664814417","media":"THOMSON REUTERS","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2664814417?lang=en_us&edition=fundamental","pubTime":"2026-09-02 21:04","pubTimestamp":1788354266,"startTime":"0","endTime":"0","summary":null,"market":"nz","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://api.refinitiv.com/data/news/v1/stories/urn:newsml:reuters.com:20260902:nFWN44T1AZ:2","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"reuters_en_live","symbols":["BK1574","BK1583","BK1587","02162","BK1161"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2664144128","title":"KeyMed Biosciences - Enters Exclusive Licensing Agreement with Aeira Pte for Stapokibart Injection","url":"https://stock-news.laohu8.com/highlight/detail?id=2664144128","media":"THOMSON REUTERS","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2664144128?lang=en_us&edition=fundamental","pubTime":"2026-09-02 21:04","pubTimestamp":1788354266,"startTime":"0","endTime":"0","summary":null,"market":"fut","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://api.refinitiv.com/data/news/v1/stories/urn:newsml:reuters.com:20260902:nFWN44T1AZ:1","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"reuters_en_live","symbols":["02162","BK1587","BK1161","BK1574","BK1583"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2664146728","title":"Yuexiu Services Files Board, Board Committee Member List with Disclosure Duties","url":"https://stock-news.laohu8.com/highlight/detail?id=2664146728","media":"Reuters","labels":["executive"],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2664146728?lang=en_us&edition=fundamental","pubTime":"2026-09-02 20:58","pubTimestamp":1788353902,"startTime":"0","endTime":"0","summary":"Yuexiu Services files board, board committee member list with disclosure dutiesYuexiu Services named its board lineup, with Jiang Guoxiong as chairman.Executive directors: Li Huiting, Xu Jianhui, Zhan","market":"fut","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://api.refinitiv.com/data/news/v1/stories/urn:newsml:reuters.com:20260902:nNDL28yccc:1","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"executive","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["06626","BK1258","BK1229","BK1542","LU1171460220.USD","BK1240","00123","BK1587","BK1555","LU2279858448.HKD"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2664146258","title":"Yuexiu Services Appoints Chen Yujun as Non-Executive Director","url":"https://stock-news.laohu8.com/highlight/detail?id=2664146258","media":"Reuters","labels":["executive"],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2664146258?lang=en_us&edition=fundamental","pubTime":"2026-09-02 20:57","pubTimestamp":1788353841,"startTime":"0","endTime":"0","summary":"Yuexiu Services appoints Chen Yujun as non-executive directorYuexiu Services named Chen Yujun as a non-executive director, effective Sept. 2, 2026.Chen joined the board’s investment committee; he is d","market":"nz","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://api.refinitiv.com/data/news/v1/stories/urn:newsml:reuters.com:20260902:nNDL3YLxDW:1","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"executive","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["06626","BK1555","BK1587","00123","BK1240","BK1229","LU1171460220.USD","LU2279858448.HKD","BK1542","BK1258"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2664907811","title":"Kindstar Globalgene Files HKEX Next-Day Disclosure Return on Share Buyback Cancellation","url":"https://stock-news.laohu8.com/highlight/detail?id=2664907811","media":"Reuters","labels":["shareholding"],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2664907811?lang=en_us&edition=fundamental","pubTime":"2026-09-02 20:29","pubTimestamp":1788352193,"startTime":"0","endTime":"0","summary":"Kindstar Globalgene files HKEX next-day disclosure return on share buyback cancellationKindstar Globalgene filed a next-day disclosure return reporting an on-market buyback of 43,000 ordinary shares o","market":"nz","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://api.refinitiv.com/data/news/v1/stories/urn:newsml:reuters.com:20260902:nNDL7dmLq2:1","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"shareholding","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["09960","BK1587","BK1219"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"1106290006","title":"NAYUKI Spends HK$1.64 Million to Buy Back 2.35 Million Shares on September 2","url":"https://stock-news.laohu8.com/highlight/detail?id=1106290006","media":"Stock News","labels":["shareholding"],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/1106290006?lang=en_us&edition=fundamental","pubTime":"2026-09-02 19:52","pubTimestamp":1788349934,"startTime":"0","endTime":"0","summary":"NAYUKI (02150) has announced that it repurchased 2.35 million shares on September 2, 2026, at a total cost of HK$1.6395 million.The share buyback reflects the company's ongoing capital management...","market":"sh","thumbnail":"","type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"shareholding","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["02150","BK1587","BK1233","BK1616"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2664193428","title":"Nayuki Files HKEX Next-Day Disclosure Return Reporting Share Buyback at HKD 0.7 Per Share","url":"https://stock-news.laohu8.com/highlight/detail?id=2664193428","media":"Reuters","labels":["shareholding"],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2664193428?lang=en_us&edition=fundamental","pubTime":"2026-09-02 19:47","pubTimestamp":1788349664,"startTime":"0","endTime":"0","summary":"Nayuki files HKEX next-day disclosure return reporting share buyback at HKD 0.7 per shareNayuki repurchased 2,350,000 ordinary shares on Sept. 2, 2026, holding all as treasury shares; none were cancel","market":"nz","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://api.refinitiv.com/data/news/v1/stories/urn:newsml:reuters.com:20260902:nNDL4pljVc:1","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"shareholding","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["BK1233","BK1616","BK1587","02150"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"1120507560","title":"Zhang Guangdi Raises Stake in Chaoju Eye Care with Share Acquisition","url":"https://stock-news.laohu8.com/highlight/detail?id=1120507560","media":"Stock News","labels":["shareholding"],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/1120507560?lang=en_us&edition=fundamental","pubTime":"2026-09-02 19:31","pubTimestamp":1788348682,"startTime":"0","endTime":"0","summary":"Hong Kong stock exchange records show that on August 31, Zhang Guangdi increased his holdings in Chaoju Eye Care (02219) by 36,000 shares, with each share priced at HKD 2.358, bringing the total...","market":"fut","thumbnail":"","type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"shareholding","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["EWH","BK1209","BK1587","02219"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2664165428","title":"Bairong Files HKEX Next-Day Disclosure Return Reporting Share Repurchase at HKD 5.39 Each","url":"https://stock-news.laohu8.com/highlight/detail?id=2664165428","media":"Reuters","labels":["shareholding"],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2664165428?lang=en_us&edition=fundamental","pubTime":"2026-09-02 19:21","pubTimestamp":1788348078,"startTime":"0","endTime":"0","summary":"Bairong files HKEX next-day disclosure return reporting share repurchase at HKD 5.39 eachBairong repurchased 616,500 WVR ordinary shares (type B) on Sept. 2, holding all as treasury shares.Buyback pri","market":"fut","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://api.refinitiv.com/data/news/v1/stories/urn:newsml:reuters.com:20260902:nNDL8qW4VH:1","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"shareholding","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["06608","BK1575","BK1583","BK1587","BK1109","BK1131"],"isVideo":false,"video":null,"gpt_icon":0}],"pageSize":20,"totalPage":10,"pageCount":8,"totalSize":200,"code":"91000000","status":"200"}]}}